These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28365224)

  • 21. Lectin-Mediated pH-Sensitive Doxorubicin Prodrug for Pre-Targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects.
    Yao M; Ma X; Zhang X; Shi L; Liu T; Liang X; Zhao H; Li X; Li L; Gao H; Jia B; Wang F
    Theranostics; 2019; 9(3):747-760. PubMed ID: 30809306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
    Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
    Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug-drug conjugate for cancer therapy.
    Huang P; Wang D; Su Y; Huang W; Zhou Y; Cui D; Zhu X; Yan D
    J Am Chem Soc; 2014 Aug; 136(33):11748-56. PubMed ID: 25078892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.
    Guo Y; Chu M; Tan S; Zhao S; Liu H; Otieno BO; Yang X; Xu C; Zhang Z
    Mol Pharm; 2014 Jan; 11(1):59-70. PubMed ID: 24229050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. pH- and NIR Light-Responsive Polymeric Prodrug Micelles for Hyperthermia-Assisted Site-Specific Chemotherapy to Reverse Drug Resistance in Cancer Treatment.
    Li Z; Wang H; Chen Y; Wang Y; Li H; Han H; Chen T; Jin Q; Ji J
    Small; 2016 May; 12(20):2731-40. PubMed ID: 27043935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity.
    Duhem N; Danhier F; Pourcelle V; Schumers JM; Bertrand O; Leduff CS; Hoeppener S; Schubert US; Gohy JF; Marchand-Brynaert J; Préat V
    Bioconjug Chem; 2014 Jan; 25(1):72-81. PubMed ID: 24328289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Redox dual-responsive paclitaxel-doxorubicin heterodimeric prodrug self-delivery nanoaggregates for more effective breast cancer synergistic combination chemotherapy.
    Wang Y; Wang J; Yang L; Wei W; Sun B; Na K; Song Y; Zhang H; He Z; Sun J; Wang Y
    Nanomedicine; 2019 Oct; 21():102066. PubMed ID: 31351237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
    Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
    Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Doxorubicin-loaded NaYF4:Yb/Tm-TiO2 inorganic photosensitizers for NIR-triggered photodynamic therapy and enhanced chemotherapy in drug-resistant breast cancers.
    Zeng L; Pan Y; Tian Y; Wang X; Ren W; Wang S; Lu G; Wu A
    Biomaterials; 2015 Jul; 57():93-106. PubMed ID: 25913254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance.
    Johansson K; Ito M; Schophuizen CM; Mathew Thengumtharayil S; Heuser VD; Zhang J; Shimoji M; Vahter M; Ang WH; Dyson PJ; Shibata A; Shuto S; Ito Y; Abe H; Morgenstern R
    Mol Pharm; 2011 Oct; 8(5):1698-708. PubMed ID: 21851097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo.
    Cao X; Luo J; Gong T; Zhang ZR; Sun X; Fu Y
    Mol Pharm; 2015 Jan; 12(1):274-86. PubMed ID: 25469833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.
    Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X
    Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel injectable phospholipid gel co-loaded with doxorubicin and bromotetrandrine for resistant breast cancer treatment by intratumoral injection.
    Luo JW; Zhang T; Zhang Q; Cao X; Zeng X; Fu Y; Zhang ZR; Gong T
    Colloids Surf B Biointerfaces; 2016 Apr; 140():538-547. PubMed ID: 26628333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
    Shen J; He Q; Gao Y; Shi J; Li Y
    Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
    Sheng Y; You Y; Chen Y
    Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
    Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
    Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
    Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D
    Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug.
    Huang S; Fang R; Xu J; Qiu S; Zhang H; Du J; Cai S
    J Drug Target; 2011 Aug; 19(7):487-96. PubMed ID: 21284542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
    Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
    Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.